News Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- May 08, 2019Potential FDA approval of AR101 for peanut allergy expected by late January 2020; Company on target to be launch-ready in Q4 2019
BRISBANE, Calif.--(BUSINESS WIRE)--May 8, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- May 08, 2019
FARMINGDALE, N.Y., May 08, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- May 08, 2019NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (“Acerus” or “the Company”) (TSX:ASP; OTCQB:ASPCF) announced today its shares have been approved to be quoted on the OTCQB...
- May 07, 2019– Four Products Currently Under Review with the FDA –
DEER PARK, Ill., May 07, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- May 06, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP) will announce its first quarter 2019 financial and operating results on Monday May 13, 2019 before the market opens. The...
- May 06, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release first quarter 2019 financial and operating results on Thursday, May 9, 2019 after the close...
- May 02, 2019Transaction Creates Medical Device Company with Comprehensive Portfolio of Wound Care Solutions to Improve Healthcare Outcomes
FARMINGDALE, N.Y., May 02, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix”) a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical...
- May 01, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--May 1, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Apr 30, 2019
DEER PARK, Ill., April 30, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug...
- Apr 29, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has engaged Paradigm Capital Inc. (“Paradigm”) as its...
- Apr 24, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP) announced today that Edward Gudaitis, President and Chief Executive Officer of Acerus, is scheduled to present an overview...
- Apr 10, 2019
FARMINGDALE, N.Y., April 10, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices...
- Apr 09, 2019BIOLASE and TeamSmile Expand Initiative of Oral Health Day to Students in Kansas City Public SchoolsPlayers and mascot "Blue the Dog" from Sporting Kansas City will be in attendance to meet and greet the students and support the program
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, TeamSmile, the nation's premier advocacy group that supports life-changing dental care for underserved children, and the Sporting...
- Apr 03, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Apr. 3, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that
- Mar 29, 2019Total revenues of approximately $26.0 million for the fiscal year 2018 compared to $37.5 million for the fiscal year 2017.
Dallas, TX, March 29, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its fourth quarter and full year...
- Mar 29, 2019NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (the “Company”) (TSX:ASP) is pleased to announce that it has closed a non-brokered private placement (the “Private Placement”)...
- Mar 27, 2019Chargers wide receiver Geremy Davis, running back Justin Jackson and the Charger Girls to meet the students and support necessary cause
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, TeamSmile, the nation's premier advocacy group that supports life-changing dental care for underserved children, and the Los...
- Mar 25, 2019NDA filing for ET-202 Accepted for Review and Assigned PDUFA Date of October 21, 2019
DEER PARK, Ill., March 25, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug...
- Mar 25, 2019-- Company Intends to Submit European MAA in Mid-2019 --
BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 25, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Mar 18, 2019-- If Approved, AR101 Will Be the First Medicine for This Life-Threatening Condition --
BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 18, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Mar 14, 2019FDA Previously Granted DS-200 Fast Track Designation
DEER PARK, Ill., March 14, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug...
- Mar 12, 2019
MIAMI, March 12, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and...
- Mar 11, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will be presenting at the second annual LD Micro Virtual Investor Conference on Wednesday, March 13th at...
- Mar 06, 2019
FARMINGDALE, N.Y., March 06, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices...
- Mar 05, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 5, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Mar 05, 2019Enteris’ lead program, Ovarest®, is designed to address a key endometriosis patient need by enabling the oral delivery of leuprolide
Boonton, NJ – March 5, 2019 – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary oral peptide delivery technologies, announced...
- Mar 05, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP) today reported its financial results for the three and twelve-month period ended...
- Mar 05, 2019Fourth Quarter U.S. Laser Revenue Increased 51% Year Over Year
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today reported net revenue of $13.0 million and $46.2 million for the fourth quarter and year ended December 31, 2018,...
- Mar 04, 2019Proven C-Suite Executive Brings Extensive Healthcare Industry Experience to New Role
FARMINGDALE, N.Y., March 04, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices...
- Mar 04, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has filed a New Drug Submission (“NDS”) for Avanafil with...
- Feb 28, 2019FDA decision on AR101 BLA filing acceptance expected by end of March
BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 28, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Feb 28, 2019BIOLASE appoints Sinclair Dental, the fastest growing full-service dental supply company in Canada, as the exclusive distributor and representative for the sales, service and support of BIOLASE's products
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced the appointment of Sinclair Dental Co. Ltd, the fastest growing dental supply company in Canada with more than 600...
- Feb 27, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) announced today two updates relative to the Company’s NATESTO® business. First, the...
- Feb 26, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP) will announce financial results for the three and twelve month periods ending December 31, 2018 on Tuesday, March 05, 2019...
- Feb 25, 2019— AR101 Associated with 70% Reduction in Allergic Reactions Due to Accidental Exposures That Required Treatment Compared to Placebo After Dose Escalation in PALISADE —
BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 25, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Feb 25, 2019
FARMINGDALE, N.Y., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Feb 21, 2019
DEER PARK, Ill., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Feb 21, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 21, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Feb 19, 2019If Approved, EM-100 Will Be the First OTC Preservative-Free Formulation of Its Kind
LAVAL, Quebec and DEER PARK, Ill., Feb. 19, 2019 – Bausch Health Companies Inc. (NYSE/TSX: BHC) and Bausch + Lomb, its wholly owned subsidiary and a leading global eye health company, and Eton...
- Feb 13, 2019— Drug Development Advancing: Successful TADFIN Clinical Trial with NDA Filing in 2019; Two Prostate Cancer Clinical Trials Enrolling — — Company to Host Investor Conference Call on Wednesday, February 13, 2019, 8 a.m. ET —
MIAMI, Feb. 13, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and...
- Feb 12, 2019
MIAMI, Feb. 12, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and...
- Feb 11, 2019Transaction adds an additional potential 2019 product launch to Eton’s pipeline
DEER PARK, Ill., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Feb 07, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release fourth quarter 2018 financial and operating results on Tuesday, March 5, 2019 after the close...
- Feb 06, 2019
MIAMI, Feb. 06, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and...
- Feb 06, 2019
FARMINGDALE, N.Y., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Feb 04, 2019— Nine Abstracts Featured, Including Data on Longer-Term AR101 Efficacy and Safety and PALISADE Accidental Exposures —
BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 4, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Feb 04, 2019Feb. 4 event will include meet-and-greets with Dallas Mavericks players, Mavs ManiAACs, dancers, and families will learn more about the latest dental technologies, including laser treatments
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, the Dallas Mavericks and TeamSmile, the nation's premier advocacy group that supports life-changing dental care for underserved...
- Jan 29, 2019On the heels of a successful co-promotion during the recent Greater New York Dental Meeting, the two companies will offer exclusive deals and product samples for complimentary product lines at the Yankee Dental Congress and Chicago Midwinter Meeting
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today a joint product promotion with Hu-Friedy, the global leader in the manufacturing of dental instruments, at two...
- Jan 25, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX: ASP) (“Acerus” or the “Company”) is today advising that it has received a Notice of Deficiency-Withdrawal Letter...
- Jan 24, 2019New Drug Application expected to be filed in 2019
DEER PARK, Ill., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- Jan 22, 2019–Open-Label Phase 1b/2 Clinical Trial Results Expected by Year-End– — Drug Addresses Significant Unmet Medical Need —
MIAMI, Jan. 22, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that it has initiated and enrolled the first patient in a...
- Jan 22, 2019
FARMINGDALE, N.Y., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that...
- Jan 18, 2019— Proven Pharmaceutical Leader Brings Deep, Global Experience with Successful Product Launches, Commercialization and Strategic Planning —
BRISBANE, Calif.--(BUSINESS WIRE)--Jan. 18, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Jan 15, 2019
MIAMI, Jan. 15, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that four abstracts have been accepted for poster...
- Jan 14, 2019Company Plans to Submit NDA in 2019
MIAMI, Jan. 14, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that the clinical trial of the Company’s proprietary...
- Jan 11, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX: ASP) (“Acerus” or the “Company”) is today advising that it has reported an anticipated shortage of certain doses of...
- Jan 04, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Jan. 4, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies,...
- Jan 04, 2019--Patients tolerated as much as 2,000 mg of peanut protein with fewer adverse events --
LISBON, Portugal--(BUSINESS WIRE)--Jun. 4, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Jan 04, 2019
Keystone Dental Inc. ("Keystone"), the largest independent dental implant company operating in North America, has entered into a definitive agreement to merge via a stock exchange transaction with...
- Jan 03, 2019The Los Angeles Chargers Girls will also be visiting to help bring awareness to this community-driven initiative
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, and TeamSmile, the nation's premier advocacy group that supports life-changing dental care for underserved children and the...
- Jan 02, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Jan. 2, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Dec 06, 2018
Dallas, TX, December 6, 2018 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, today announced that its Board of Directors...
- Nov 12, 2018Total revenues of approximately $5.9 million for the third quarter of 2018 compared to $5.5 million for the third quarter of 2017.
Dallas, TX, November 12, 2018 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its third quarter 2018 financial...
- Nov 01, 2018DxTerity will present on Thursday, November 15, 2018 at 11:30 a.m. PT (2:30 p.m. ET) in New York
Los Angeles, CA, November 1, 2018 – DxTerity, a molecular information and diagnostics company developing at-home RNA monitoring blood tests for immune-mediated diseases, today announced that...
- Oct 21, 2018Autoimmune Profile Test (AIP) shows promise for stratifying patients based on Type I interferon expression levels
Los Angeles, CA, October 21, 2018 – DxTerity, a molecular information and diagnostics company developing at-home RNA monitoring blood tests for immune-mediated diseases, today announced that...
- Sep 24, 2018
DxTerity CEO & Founder Bob Terbrueggen will be speaking at two upcoming conferences in October: World CB & CDx in Boston, MA and Precision Medicine in Autoimmunity in Denver, CO. Dr. Terbrueggen...
- Sep 19, 2018Total revenues of approximately $6.8 million for the second quarter of 2018 compared to $6.1 million for the second quarter of 2017.
Dallas, TX, August 10, 2018 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its second quarter 2018 financial...
- Aug 31, 2018
Los Angeles, CA – PM360, a publication for marketing decision markers in the pharmaceutical, biotech, and medical device industries, recently named DxTerity’s EMPOWER Study Recruitment as a...
- Jul 02, 2018
Dallas, TX, July 2, 2018 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced that it has closed a $20 million...
- Jun 07, 2018Presentations from the >1,400 LIFT Study Lupus Cohort
Los Angeles, CA, June 13, 2018 – DxTerity, a patient-centric genomics company developing at-home RNA monitoring blood tests for immune-mediated diseases, today announced that data from the LIFT...
- May 28, 2018REDI-Dx® blood test to estimate absorbed radiation after a nuclear event
LOS ANGELES, CA – May 28, 2018 – DxTerity Diagnostics has declared conformity with the requirements of the European In Vitro Diagnostic Directive (98/79/EC) and has applied the CE mark to the...
- May 01, 2018
May is Lupus Awareness Month, sponsored by organizations like Lupus Foundation of America, Lupus LA, and The Lupus Research Alliance. DxTerity is proud to support these organizations in advancing...
- Apr 30, 2018
This May 1 and May 2, 2018, the Young Jewish Professionals Organization is hosting its annual CEO Healthcare Symposium in New York City, NY, and Bob Terbrueggen, DxTerity Founder & CEO, will be...
- Mar 29, 2018Total revenues of $37.5 million for the fiscal year 2017 compared to $22.4 million for the fiscal year 2016.
Dallas, TX, March 29, 2018 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its fourth quarter and full year...
- Mar 29, 2018
The following tables provide a reconciliation of SWK’s reported (GAAP) income before provision for income tax to SWK’s adjusted net income attributable to SWK Holdings Corporation stockholders...
- Mar 15, 2018Total revenues of $6.8 million for the first quarter of 2018 compared to $14.9 million for the first quarter of 2017.
Dallas, TX, May 14, 2018 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its first quarter 2018 financial results.
- Jan 17, 2018
The Precision Medicine World Conference (PMWC) 2018 will take place in Silicon Valley on January 22-24, 2018. This year, we’re excited to announce that DxTerity Founder & CEO Bob Terbrueggen...
- Nov 10, 2017Total revenues of approximately $5.5 million for the third quarter of 2017 compared to $4.2 million for the third quarter of 2016.
Dallas, TX, November 10, 2017 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its third quarter 2017 financial...
- Nov 05, 2017
DxTerity, a patient-centric genomics company developing at-home genomic monitoring blood tests for immune mediated diseases, today announced that data on the BRAVO Study in which participants with...
- Sep 21, 2017
DxTerity announced today that it is collaborating with the City of Hope Medical Center on the clinical development of a blood test that could possibly predict whether cancer patients about to...
- Aug 14, 2017Total revenues of approximately $6.1 million for the second quarter of 2017 compared to $8.6 million for the second quarter of 2016.
Dallas, TX, August 10, 2017 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its second quarter 2017 financial...
- May 10, 2017Total revenues of approximately $14.9 million for the first quarter of 2017 compared to $5.2 million for the first quarter of 2016.
Dallas, TX, May 10, 2017 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its first quarter 2017 financial results.
- Mar 18, 2017Total revenues of $22.4 million for the fiscal year 2016 compared to $23.5 million for the fiscal year 2015
Dallas, TX, March 17, 2017 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its fourth quarter and full year...
- Nov 10, 2016Total revenues of $4.2 million for the third quarter of 2016 compared to $5.7 million for the third quarter of 2015
Dallas, TX, November 8, 2016 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its third quarter 2016 financial...
- Oct 24, 2016
(Los Angeles, CA) – DxTerity Diagnostics announced today that it has signed a multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA), which is a division of...
- Aug 12, 2016Total revenues of $8.6 million for the three months ended June 2016 compared to $5.4 million for the second quarter of 2015
Dallas, TX, August 10, 2016 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its second quarter 2016 financial...
- May 13, 2016Total revenues of approximately $5.2 million for the first quarter of 2016.
Dallas, TX, May 13, 2016 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its first quarter 2016 financial results.
- Apr 12, 2016Total revenues increased by 35% to approximately $23.5 million for the fiscal year of 2015, compared to $17.4 million for the fiscal year of 2014
Dallas, TX, March 23, 2016 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced today its fourth quarter and full...
- Mar 02, 2016Comprehensive solution makes accessing the right patients anywhere, anytime fast and affordable
DxTerity today announced the launch of its Direct-to-Patient (D2P) platform for population scale genomic studies. With the launch of the D2P platform, DxTerity provides much needed innovation in...
- Nov 17, 2015Total revenues increased by 53% to approximately $5.7 million for the third quarter of 2015, compared to $3.7 million for the third quarter of 2014
Dallas, TX, November 16, 2015 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced today its third quarter 2015...
- Sep 17, 2015
Dallas, TX –– 9/16/15 – SWK Holdings Corporation (OTCQB: SWKH) (“SWK” or the “Company”), a life science focused specialty finance company, announced a clarification on the timing of...
- Aug 14, 2015Total revenues increased by 61% to approximately $5.4 million for the second quarter of 2015, compared to $3.4 million for the second quarter of 2014
Dallas, TX, August 14, 2015 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its second quarter 2015 financial...
- Apr 17, 2015Net income and adjusted net income to SWK stockholders of $20.8 million, or $0.32 per share, and $11.2 million, or $0.17 per share, respectively, for fiscal year 2014 vs. $12.9 million, or $0.31 per share, and $3.2 million, or $0.08 per share, respectively, for fiscal year 2013
Dallas, TX, March 30, 2015 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced today its fourth quarter and full...
- Mar 22, 2015Total revenues increased by 58% to approximately $5.8 million for the first quarter of 2015, compared to $3.7 million for the first quarter of 2014
Dallas, TX, May 11, 2015 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced today its first quarter 2015 financial...
- Nov 05, 2014GAAP net income to SWK stockholders of $0.4 million, or $0.01 per share, and, $3.3 million, or $0.07 per share, for the three and nine month periods ending September 30, 2014, respectively, vs. $0.6 million, or $0.01 per share and $1.1 million, or $0.03 per share, for 2013
Dallas, TX, November 3, 2014 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced today its third quarter 2014...
- Oct 20, 2014
Dallas, Texas, October 20, 2014 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced that it established a record...
- Apr 18, 2014
Dallas, TX, August 18, 2014 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced that on August 18, 2014 that it has...
- Apr 01, 2014Net income and adjusted net income to SWK stockholders of $12.9 million, or $0.31 per share, and $3.0 million, or $0.07 per share, respectively, for fiscal year 2013 vs. a loss of $1.4 million, or $(0.03) per share, for 2012
Dallas, TX, March 31, 2013 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced today its fourth quarter and full...
- Sep 09, 2013Raises Ownership Limit for Carlson Capital, L.P.
DALLAS, Sept. 9, 2013 (GLOBE NEWSWIRE) — SWK Holdings Corporation (SWKH) (“SWK” or the “Company”), a life science focused specialty finance company, announced today that it has closed a...
- Aug 01, 2013
Dallas, TX, August 1, 2013 – SWK Holdings Corporation (“SWK” or the “Company”) (SWKH:OB) today announced that it has set Wednesday, September 18, 2013, as the date of its 2013 Annual...